Atlas Trials

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Clinical trial NCT02457598 · TERMINATED

Trial details

NCT number
NCT02457598
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Malignancies
Start date
2015-06-16
Primary completion
2024-09-25
Enrollment
203

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.